U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C10H12N4O5.3C9H9NO3.3C5H13NO
Molecular Weight 1115.2325
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INOSINE PRANOBEX

SMILES

CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC2=CC=C(C=C2)C(O)=O.CC(=O)NC3=CC=C(C=C3)C(O)=O.OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)N5C=NC6=C5N=CNC6=O

InChI

InChIKey=YLDCUKJMEKGGFI-QCSRICIXSA-N
InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;;;/m1....../s1

HIDE SMILES / InChI

Description

Inosine pranobex is an antiviral drug that is a combination of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a ratio of 1 to 3. Inosine pranobex is used to treat mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. The in vivo antiviral and activity of inosine pranobex is believed to result from an enhancement of host immune responses due to the drug. The drug does not by itself stimulate resting lymphocytes, but augments immunological processes by lymphocytes once they have been triggered by mitogens or viral antigens.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
IMUNOVIR
Primary
IMUNOVIR
Primary
IMUNOVIR

PubMed

Sample Use Guides

In Vivo Use Guide
Mucocutaneous herpes simplex: 1 g q.d.s. (4g daily), for 7 -14 days. Genital warts: 1g t.d.s. (3g daily), for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser. Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, in divided does every 4 hours.
Route of Administration: Oral
In Vitro Use Guide
Inosine pranobex has been shown to stimulate various indices of metabolic activity of macrophages and monocytes. In vitro exposure to inosine pranobex or to 24-hour supernatants obtained from mononuclear cells pretreated with the drug restored chemotaxis to normal or near normal levels. Incubation with inosine pranobex in vitro stimulated the production of interleukin-l (lymphocyte activating factor) in human monocytes.